Global Irritable Bowel Syndrome (IBS) Therapeutics Market by Type (Blautix (Strain), Bekinda (IBD), SY010, Tenapanor), By Application (Hospital, Research) And By Region - North America, Latin America, Europe, Asia Pacific and Middle East & Africa. The global IBS therapeutics market is expected to grow at a CAGR of 7.2% during the forecast period from 2021 to 2030. The market is driven by factors such as increasing prevalence of IBS in the population and rising awareness about the disease among people. The key players in this market are developing new drugs for treating IBS symptoms and improving quality of life for patients with IBS. -IBS is a chronic condition that affects the large intestine and causes abdominal pain, bloating, constipation, and diarrhea. -The global IBS therapeutics market is expected to grow at a CAGR of 5.2% from 2017 to 2025. -The global IBS therapeutics market was valued at $1.5 billion in 2016 and is expected to reach $2.4 billion by 2025 with an estimated CAGR of 5.2%. -The key factors driving the growth of this market are increasing prevalence rates of IBS, rising awareness about the disease among patients and healthcare providers, growing number of clinical trials for new drugs in pipeline for treatment of IBS symptoms such as abdominal pain or diarrhea, increasing adoption rate for new drugs by physicians due to their efficacy in treating symptoms associated with IBS such as abdominal pain or diarrhea etc,. -In addition, there are various other factors which are driving the growth of this market such as increase in geriatric population globally which has increased prevalence rates for diseases like irritable bowel syndrome (IBS), rise in incidence rates due to lifestyle changes like stress etc,.
Industry Growth Insights published a new data on “Irritable Bowel Syndrome (IBS) Therapeutics Market”. The research report is titled “Irritable Bowel Syndrome (IBS) Therapeutics Market research by Types (Blautix (Strain), Bekinda (IBS-D), SYN-010, Tenapanor), By Applications (Hospital, Research), By Players/Companies Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Ardelyx, Astellas Pharma, Novartis, GlaxoSmithKline, Ironwood Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Irritable Bowel Syndrome (IBS) Therapeutics Market Research Report
By Type
Blautix (Strain), Bekinda (IBS-D), SYN-010, Tenapanor
By Application
Hospital, Research
By Companies
Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Ardelyx, Astellas Pharma, Novartis, GlaxoSmithKline, Ironwood Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Irritable Bowel Syndrome (IBS) Therapeutics Market Report Segments:
The global Irritable Bowel Syndrome (IBS) Therapeutics market is segmented on the basis of:
Types
Blautix (Strain), Bekinda (IBS-D), SYN-010, Tenapanor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Synergy Pharmaceuticals
- Sucampo Pharmaceuticals
- Valeant Pharmaceuticals International
- Ardelyx
- Astellas Pharma
- Novartis
- GlaxoSmithKline
- Ironwood Pharmaceuticals
Highlights of The Irritable Bowel Syndrome (IBS) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Blautix (Strain)
- Bekinda (IBS-D)
- SYN-010
- Tenapanor
- By Application:
- Hospital
- Research
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Irritable Bowel Syndrome (IBS) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Irritable Bowel Syndrome (IBS) Therapeutics is a group of medications used to treat the symptoms of IBS, including diarrhea, constipation, and abdominal pain. These medications can help improve your quality of life by relieving your symptoms.
Some of the key players operating in the irritable bowel syndrome (ibs) therapeutics market are Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Ardelyx, Astellas Pharma, Novartis, GlaxoSmithKline, Ironwood Pharmaceuticals.
The irritable bowel syndrome (ibs) therapeutics market is expected to grow at a compound annual growth rate of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Irritable Bowel Syndrome (IBS) Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Irritable Bowel Syndrome (IBS) Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Irritable Bowel Syndrome (IBS) Therapeutics Market - Supply Chain
4.5. Global Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast
4.5.1. Irritable Bowel Syndrome (IBS) Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Irritable Bowel Syndrome (IBS) Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Irritable Bowel Syndrome (IBS) Therapeutics Market Absolute $ Opportunity
5. Global Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Type
5.3.1. Blautix (Strain)
5.3.2. Bekinda (IBS-D)
5.3.3. SYN-010
5.3.4. Tenapanor
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Research
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Irritable Bowel Syndrome (IBS) Therapeutics Demand Share Forecast, 2019-2026
9. North America Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Research
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Type
9.7.1. Blautix (Strain)
9.7.2. Bekinda (IBS-D)
9.7.3. SYN-010
9.7.4. Tenapanor
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Irritable Bowel Syndrome (IBS) Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Research
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Type
10.7.1. Blautix (Strain)
10.7.2. Bekinda (IBS-D)
10.7.3. SYN-010
10.7.4. Tenapanor
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Irritable Bowel Syndrome (IBS) Therapeutics Demand Share Forecast, 2019-2026
11. Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Research
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Type
11.7.1. Blautix (Strain)
11.7.. Bekinda (IBS-D)
11.7.3. SYN-010
11.7.4. Tenapanor
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Irritable Bowel Syndrome (IBS) Therapeutics Demand Share, 2019-2026
12. Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Research
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Type
12.7.1. Blautix (Strain)
12.7.2. Bekinda (IBS-D)
12.7.3. SYN-010
12.7.4. Tenapanor
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Research
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Size and Volume Forecast by Type
13.7.1. Blautix (Strain)
13.7.2. Bekinda (IBS-D)
13.7.3. SYN-010
13.7.4. Tenapanor
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Irritable Bowel Syndrome (IBS) Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Irritable Bowel Syndrome (IBS) Therapeutics Market: Market Share Analysis
14.2. Irritable Bowel Syndrome (IBS) Therapeutics Distributors and Customers
14.3. Irritable Bowel Syndrome (IBS) Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Synergy Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sucampo Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Valeant Pharmaceuticals International
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Ardelyx
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Astellas Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Ironwood Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook